Screening of inherited metabolic abnormalities in 56 children with intractable epilepsy

Xiaoming Liu1, Rui Li1, Shengzhi Chen1

  • 1Department of Neurology, Xuzhou Children's Hospital, Xuzhou, Jiangsu 221002, P.R. China.

Insights

Inherited metabolic abnormalities are common in children with intractable epilepsy (IE). Early screening for these conditions, especially in infantile spasms, can improve treatment outcomes and prognosis.

Area of Science:

  • Pediatric Neurology
  • Metabolic Disorders

Background:

  • Epilepsy is a prevalent neurological condition in children, often managed with anti-epileptic drugs.
  • Intractable epilepsy (IE) in children is characterized by persistent, recurrent seizures despite treatment.
  • Identifying underlying causes like inherited metabolic abnormalities is crucial for effective management.

Purpose of the Study:

  • To investigate inherited metabolic abnormalities in children diagnosed with intractable epilepsy (IE).
  • To correlate metabolic findings with clinical manifestations and neurological assessments in pediatric IE.
  • To establish the significance of early metabolic screening for improving treatment and prognosis in children with IE.

Main Methods:

  • Analyzed urine and blood samples from 56 children with IE (experimental group) and 56 successfully treated children (control group).
  • Utilized gas chromatography-mass spectrometry and tandem mass spectrometry for metabolic screening of amino, organic, and fatty acids.
  • Conducted urine routine, hepatic function tests, blood biochemistry, encephalon imaging (CT/MRI), and brain stem-evoked potential (auditory/optical) assessments.

Main Results:

  • Of 27 IE children with abnormal screening, 11 (19.6%) were diagnosed with inherited metabolic diseases.
  • Abnormal urine screening was significantly correlated with inherited metabolic abnormalities (P<0.05).
  • Inherited metabolic abnormality was identified as a common factor in IE pathogenesis, particularly in infantile spasms.

Conclusions:

  • Inherited metabolic abnormalities are a significant contributing factor to intractable epilepsy in children.
  • Early screening for inborn metabolic disorders in pediatric IE patients is recommended.
  • Timely diagnosis and treatment of metabolic abnormalities can improve the prognosis for children with intractable epilepsy.

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
990
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
5.8K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
313